Physician profile
William Ferrar
NPI 1649251935
$6,746.53
in general payments reported to CMS, 2019-2025
33 companies · $140 in 2025
The $140 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,814 · 2020: $622 · 2021: $1,777 · 2022: $1,393 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,570.83 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $800.00 | 2021 | |
| Abbvie INC. | $437.38 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.84 | 2019-2021 | |
| Pfizer INC. | $414.45 | 2019-2020 | |
| Novo Nordisk INC | $389.76 | 2019 | |
| Astellas Pharma US INC | $336.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $310.51 | 2019-2022 | |
| Allergan, INC. | $262.15 | 2019 | |
| Esperion Therapeutics, INC. | $202.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $143.61 | 2019 | |
| Smith+Nephew, INC. | $140.33 | 2025 | Real Intelligence |
| Lilly USA, LLC | $138.39 | 2019-2021 | |
| Glaxosmithkline, LLC. | $136.45 | 2019-2022 | |
| Insightec,INC | $135.63 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.55 | 2019 | |
| Dynavax Technologies Corporation | $116.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $93.81 | 2021 | |
| Edwards Lifesciences Corporation | $90.45 | 2019 | |
| Horizon Therapeutics Plc | $79.21 | 2022 | |
| Abbott Laboratories | $58.41 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.10 | 2022 | |
| Sanofi Pasteur INC. | $27.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.73 | 2019-2022 | |
| Almatica Pharma LLC | $23.40 | 2021 | |
| Genzyme Corporation | $17.81 | 2022 | |
| Mylan Specialty L.P. | $17.28 | 2022 | |
| Endo Pharmaceuticals INC. | $13.77 | 2019 | |
| Medtronic USA, INC. | $13.15 | 2020 | |
| Merck Sharp & Dohme LLC | $12.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ferrar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.